Rodríguez-Violante M, Cervantes-Arriaga A, Morales-Briceño H, Martínez-Ramírez D, Martínez-Bernal F, Corona T

Language: Spanish
References: 26
Page: 296-300
PDF size: 182.99 Kb.

ABSTRACT

Introduction: The atypical parkinsonisms include both alpha-synucleinopathies and tauopathies and are considered part of the differential diagnosis of Parkinson’s disease. Objective: To determine the prevalence of atypical parkinsonisms in the movement disorders clinic at the National Institute of Neurology and Neurosurgery. Methods: We analyzed all records of patients admitted to the National Institute of Neurology and Neurosurgery with a diagnosis of parkinsonism or rigid-akinetic syndrome in the period between 2003 and 2010. Diagnosis was recorded from the clinical file and compared with the diagnostic criteria for each of the parkinsonism syndromes for confirmatory purposes. Results: A total of 647 cases were reviewed obtaining a final sample of 36 (5.6%) patients with atypical parkinsonism. A total of 10 (28%) patients with progressive supranuclear palsy were identified, 10 (28%) cases of dementia with Lewy bodies, 5 (14%) cases with multiple system atrophy, 2 (7%) with frontotemporal dementia, one (3%) case with corticobasal degeneration and another (3%) with parkinsonismdystonia syndrome. There were 7 (19%) cases with unclassifiable parkinsonism. Conclusions: The frequency of atypical parkinsonism was 5.6%, which is consistent with other reports. However, distribution by specific type differs. Moreover, there is a considerable number of unclassifiable parkinsonisms.

REFERENCES

1. Bohlhalter S, Kagi G. Parkinsonism: heterogeneity of a common neurological syndrome. Swiss Med Wkly 2011; 141:13293.

2. Wenning GK, Tolosa E, Litvan I. Milestones in atypical and secondary parkinsonisms. Mov Disord 2011; 26(6): 1083-95.

3. Horvath J, Burkhard PR, Bouras C, Kövari E. Etiologies of Parkinsonism in a Century-Long Autopsy-Based Cohort. Brain Pathol 2012 Jun 15. [Epub ahead of print].

4. Gibb WR, Lees AJ. The significance of the Lewy body in the diagnosis of idiopathic Parkinson’s disease. Neuropathol Appl Neurobiol 1989; 15: 27-44.

5. Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele- Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996; 47: 1-9.

6. Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanoski JQ, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008; 71: 670-6.

7. McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65(12): 1863-72.

8. Litvan I, Bhatia KP, Burn DJ, Goetz CG, Lang AE, McKeith I, et al. SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders. Mov Disord 2003; 18: 467-86.

9. McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ, et al. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal dementia and Pick’s disease. Arch Neurol 2001; 58: 1803-9.

10. Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. Arch Neurol 1964; 10: 333-59.

11. Litvan I. Update on epidemiological aspects of progressive supranuclear palsy. Mov Disord 2003; 18: S43-50.

12. Wenning GK, Colosimo C, Geser F, Poewe W. Multiple system atrophy. Lancet Neurol 2004; 3(2): 93-103.

13. Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiples system atrophy: a cross sectional study. Lancet 1999; 354: 1771-5.

14. Rebeiz JJ, Kolodny EH, Richardson EP, Jr. Corticodentatonigral degeneration with neuronal achromasia. Arch Neurol 1968; 18(1): 20-33.

15. Weisman D, McKeith I. Dementia with Lewy bodies. Semin Neurol 2007; 27: 42-7.

16. Ioannidis P, Konstantinopoulou E, Maiovis P, Karacostas D. The frontotemporal dementias in a tertiary referral center: Classification and demographic characteristics in a series of 232 cases. J Neurol Sci 2012; 18: 171-3.

17. Rabinovici GD, Miller BL. Frontotemporal lobar degeneration: epidemiology, pathophysiology, diangnosis and management. CNS Drugs 2010; 24: 375-98.

18. Osaki Y, Morita Y, Kuwahara T, Miyano I, Doi Y. Prevalence of Parkinson’s disease and atypical parkinsonism syndromes in a rural Japnaese district. Acta Neurol Scand 2011; 124: 182-7.

19. Winter Y, Bezdolnyy Y, Katunina E, Avakjan G, Reese JP, Klotsche J, et al. Incidenec of Parkinson´s disease and atypical parkinsonism: Russian population-based study. Mov Disord 2010: 25: 349-56.

20. Linde J, Stenlud H, Rorsgren L. Incidence of Parkinson’s disease and parkinsonism in Northern Sweden: a population-based study. Mov Disord 2010; 25: 341-8.

21. Wermuth L, Lassen CF, Himmerslev L, Olsen J, Ritz B. Validation of hospital register-based diagnosis of Parkinson’s disease. Dan Med J 2012; 59: A4391.

22. Colosimo C, Morgante L, Antonini A, Barone P, Avarello TP, Bottacchi E, et al. Non-motor symptoms in atypical and secondary parkinsonism: the PRIAMO study. J Neurol 2010; 257: 5-14.

23. Katzenschagler R, Cardozo A, Avila Cobo MR, Tolosa E, Lees AJ. Unclassifiable parkinsonism in two European tertiary referral centres for movement disorders. Mov Disord 2003; 18: 1123-31.

24. Schrag A, Ben-Sholmo Y, Quinn N. How valid is the clinical diagnosis of Parkinson’s disease in the community? J Neurol Neurosurg Neuropsychiatry 2002; 73:529-34. Low sensitivity in clinical diagnoses of dementia with Lewy bodies. J Neurol 2010; 257: 359-66.

25. Rodríguez-Violante M, López-Ruiz M, Estrada-Bellmann I, Cervantes-Arriaga A. Implementación de una evaluación corta estandarizada de la enfermedad de Parkinson. Rev Mex Neuroci 2012; 13: 183-6.

26. Cervantes-Arriaga A, Rodríguez-Violante M, Vélez-Cedeño A, Alatriste-Booth V. Estudio piloto de validación de la escala de SCOPA-sueño en pacientes mexicanos con enfermedad de Parkinson. Rev Mex Neuroci 2011; 12: 346-51.